2017 Year in Review and Message from the Editors to Our Reviewers
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 11, 2018
- Accepted in final form January 11, 2018
- First Published February 20, 2018.
Author Disclosures
- Stefan M. Pulst, MD, Dr med, Editor,
- Nicholas Elwood Johnson, MD, Deputy Editor,
- Massimo Pandolfo, MD, FAAN,
- Raymond P. Roos, MD, FAAN and
- Jeffery M. Vance, MD, PhD, Associate Editors
- Stefan M. Pulst, MD, Dr med, Editor,
NONE
NONE
NONE
Journal of Cerebellum, NeuroMolecular Medicine, Experimental Neurology, Neurogenetics, Nature Clinical Practice Neurology Editor-in-Chief: Neurology: Genetics
Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Shwannomin-binding-proteins; Compositions and methods for spinocerebellar ataxia
The Ataxias (Churchill Livingston, 2007), Genetics in Neurology (ANN Press, 2005), Genetics of Movement Disorders (Academic Press, 2003), Neurogenetics (Oxford University Press, 2000), Molecular Genetic Testing in Neurology, 2nd - 5th (AAN Press, 1996)
NONE
Ataxion Therapeutics
Athena Diagnostics, Inc.
NONE
NONE
NONE
(1) 2010-2012 National Institutes of Health (RC1NS068897): CLINICAL RESEARCH CONSORTIUM FOR SPINOCEREBELLAR ATAXIAS, 9/1/2009-8/31/2012 (Principal Investigator of genomics core and site PI). (2) 2010-2013 National Institutes of Health (RC4NS073009): Drug discovery for Spinocerebellar ataxia type 2 (SCA2). 9/1/2010-8/31/2013 (Principle Investigator, Co-PI, D. Scoles). (3) 2013-2015 National Institutes of Health (R21NS081182): Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2. 07/01/2013 to 06/30/2015 (Co- PI with D. Scoles). (4) 2013-2016 National Institutes of Health (R21NS079852): Identification of a mutation causing Purkinje cell degeneration in the rat. 03/01/2013 to 02/28/2016. (Principle Investigator). (5) 2014-2021 National Institutes of Health (RO1NS33123): Spinocerebellar ataxia type 2: gene and gene product. 9/30/14-6/30/2021. (Principal Investigator).
NONE
National Ataxia foundation (mentor for fellowship award)
NONE
Cedars-Sinai Medical Center
NONE
NONE
NONE
NONE
- Nicholas Elwood Johnson, MD, Deputy Editor,
NONE
NONE
NONE
Neurology: Genetics, Associate Editor, 1.5 years
NONE
NONE
NONE
(1) AMO Pharma, (2) AveXis
NONE
NONE
NONE
(1) Ionis Pharmaceuticals, (2) Biogen Idec, (3) Valerion Therapeutics, (4) Cytokinetics, (5) Acceleron
(1) NINDS, 1K23NS091511-01, 2 years
NONE
Muscular Dystrophy Association, (2) Myotonic Dystrophy Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Massimo Pandolfo, MD, FAAN,
(1) Apopharma, DSMB and consulting (2) Voyager Therapeutics, Scientific Advisory Board
NONE
NONE
(1) Acta Neurologica Belgica, Editorial Board Member, 2011- (2) Orphanet Journal of Rare Diseases, Editorial Board Member, 2013- (3) Neurology Genetics, Associate Editor, 2015-
(1) Direct molecular diagnosis of Friedreich?s ataxia. M. Pandolfo, L. Montermini, M.D. L. Molto, M. Koenig, V. Campuzano, M. Cossee. US patent (2000) 6, 150, 091, WO patent (1997) 9705234.
NONE
NONE
(1) Biomarin (2) UCB
NONE
NONE
NONE
(1) Biomarin
(1) Fonds National de la Recherche Scientifique (Belgium)
NONE
(1) Offrez-moi-la-lune (2) Friedreich's Ataxia Research Alliance (3) Association Belge contre les Maladies neuro-Musculaires
NONE
NONE
(1) Friedreich's ataxia diagnostic test, Athena Diagnostics, since 1997
NONE
NONE
NONE
- Raymond P. Roos, MD, FAAN and
NONE
NONE
NONE
Virology, Editorial Board, 2013-present Neurology Genetics, Associate Editor, 2015-present MedLink, Senior Associate Editor, 2001-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NINDS, NIH, 1 R21 NS078142-01 (PI) 3/15/12-1/31/15
NONE
(i) Ralph and Marian Falk Medical Research Trust (ii) Judith and Jean Pape Adams Charitable Foundation (iii) ALS Association (iv) Chicago Biomedical Consortium
NONE
NONE
NONE
Ionis Pharmaceuticals, 2014-present Stock/Stock Options, Medical Equipment & Materials: (i) Merck (ii) Amgen (iii) Express Scripts
NONE
NONE
- Jeffery M. Vance, MD, PhD, Associate Editors
NONE
NONE
NETPR, Department of Defense, review section. NIH, Meetings
America Journal of Neurodegenerative Diseases, editorial board, 3 year Neurology Genetics, Associate Editor, 2 year
1) method of detecting Charcot-Marie-Tooth disease type 2A 2) TRPC6 involved in glomerulonephritis 3) Methods for identifying an individual at increased risk of developing coronary artery disease
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NINDS 5P50NS071674 PI, 16y DOD/ W81XWH-14-1-0097 PI, 2y NIH/NINDS 1R25NS090624 PI, 2y
NONE
Hussman Foundation
NONE
NONE
Royalty, Duke University, 7y for CMT2A with Athena
NONE
NONE
NONE
Article usage
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.